Taysha Gene Therapies (TSHA) Consolidated Net Income: 2022-2025
Historic Consolidated Net Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$30.9 million.
- Taysha Gene Therapies' Consolidated Net Income fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
- As of Q3 2025, Taysha Gene Therapies' Consolidated Net Income stood at -$30.9 million, which was down 23.92% from -$24.9 million recorded in Q2 2025.
- Taysha Gene Therapies' Consolidated Net Income's 5-year high stood at -$15.0 million during Q4 2023, with a 5-year trough of -$55.1 million in Q4 2022.
- In the last 3 years, Taysha Gene Therapies' Consolidated Net Income had a median value of -$20.1 million in 2025 and averaged -$21.3 million.
- Per our database at Business Quant, Taysha Gene Therapies' Consolidated Net Income soared by 72.69% in 2023 and then slumped by 43.36% in 2024.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' Consolidated Net Income stood at -$55.1 million in 2022, then soared by 72.69% to -$15.0 million in 2023, then declined by 21.39% to -$18.3 million in 2024, then declined by 29.62% to -$30.9 million in 2025.
- Its last three reported values are -$30.9 million in Q3 2025, -$24.9 million for Q2 2025, and -$20.1 million during Q1 2025.